LQDALQDAHealthcare · Drug Manufacturers - Specialty & Generic

LQDA Stock Forecast: Liquidia Corp. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$56
−0.55% on the day

The 8 Wall Street analysts covering Liquidia Corp. hold a median 12-month price target of $67 — +17.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.1B
Ticker Nerd rank
97/ 100
Median analyst target
$67
Analysts covering
8
Revenue$171.7M+1842.7% y/y
Operating income$85.5M
Net income$74.7M
Free cash flow$68.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.2%
1M
+64.3%
YTD
+63.6%
1Y
+86.8%
From 52W high
−38.0%
From 52W low
+117.8%
$26
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LQDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Liquidia Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
97/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Value
98
Growth
88
Momentum
87
Accruals
82
Issuance
70
Volatility
68
Revisions
58
Size
22

Quality (98): The business earns solid, repeatable profits on what it owns.

Revisions (58): Analysts have, on balance, been cutting their forecasts.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LQDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LQDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26LQDAHigh $87Median $67Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
6 Buy2 Hold0 Sell
Low $40Median $67High $87

The green dot is the last close — the median target sits +17.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Nov 2026HC Wainwright & Co.AssumesBuy$76
11 Nov 2026NeedhamMaintainsBuy$58 → $66
11 Nov 2026Wells FargoMaintainsEqual-Weight$33 → $40
10 Nov 2026BTIGMaintainsBuy$70 → $87
10 Nov 2026JefferiesMaintainsBuy$55 → $62
15 Oct 2026HC Wainwright & Co.MaintainsBuy—
15 Oct 2026HC Wainwright & Co.MaintainsBuy$58 → $65
14 Oct 2026BTIGUpgradeBuy$70
14 Oct 2026BTIGUpgradeBuy—
14 Oct 2026LifeSci CapitalUpgradeOutperform$59
14 Oct 2026LifeSci CapitalUpgradeOutperform—
14 Oct 2026NeedhamMaintainsBuy—
14 Oct 2026NeedhamMaintainsBuy$72 → $58
14 Oct 2026Wells FargoMaintainsEqual-Weight—
14 Oct 2026Wells FargoMaintainsEqual-Weight$30 → $33
2 Oct 2026HC Wainwright & Co.MaintainsBuy$130 → $58
2 Oct 2026HC Wainwright & Co.MaintainsBuy—
2 Oct 2026Wells FargoDowngradeEqual-Weight$108 → $30
2 Oct 2026Wells FargoDowngradeEqual-Weight—
1 Oct 2026BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LQDA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LQDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Liquidia Corp. returned +86.8% against +12.2% for the S&P 500, dividends included.

LQDA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26LQDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LQDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−97.7%
Analysts raising
0
Analysts cutting
4
Fundamentals

Liquidia Corp. (LQDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
34.5×

Cheaper than 21% of US stocks

Price / sales
8.2×

Cheaper than 15% of US stocks

Price / book
25.7×

Cheaper than 4% of US stocks

EV / EBITDA
16.5×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
314.6%

Higher than 97% of US stocks

Earnings growth (YoY)
1842.7%

Higher than 99% of US stocks

Gross margin
93.3%

Higher than 97% of US stocks

Operating margin
47.1%

Higher than 96% of US stocks

Net margin
−15.1%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−154.0%

Higher than 9% of US stocks

Return on assets
38.2%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Liquidia Corp. (LQDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Liquidia Corp. has a market value of $5.1B and an enterprise value of $4.9B.

  • Revenue in the twelve months to 30 June 2026: $450.9M. The latest quarter grew 314.6% year on year.

  • Net income over the same four quarters: $138.6M, a 30.7% net margin.

  • Diluted earnings per share, trailing twelve months: $1.37.

  • Free cash flow in the twelve months to 30 June 2026: $147.7M.

  • Shares outstanding: 89.1M.

  • Trailing P/E: 34.5×; forward P/E: 16.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Liquidia Corp. employs 216 people — $2.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

LQDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
LQDALiquidia Corp.$5.1B97
SUPN.1Supernus, Inc.$6.0B89
HIMSHims & Hers Health, Inc.$4.1B12
LNTHLantheus Holdings, Inc.$6.6B98
KNSAKiniksa Pharmaceuticals International Plc$7.3B98
AMRXAmneal Pharmaceuticals, Inc.$7.4B83
AMLXAmylyx Pharmaceuticals, Inc.$3.5B60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Liquidia Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LQDA news & analysis

Liquidia: Yutrepia's PAH Franchise Has Room To Grow

Seeking Alpha · 14 Nov 2026neutral

Liquidia retained the right to market YUTREPIA for PAH under its settlement with United Therapeutics. The settlement limits the drug’s potential in PH-ILD, while YUTREPIA is already generating cash and can still be sold to PAH patients and patients already using it.

Why it matters — Paid PAH starts will indicate how much of the lost PH-ILD growth Liquidia can replace.

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Zacks Investment Research · 11 Nov 2026positive

Liquidia reported Q3 earnings and revenue above estimates, alongside a surge in Yutrepia sales. The excerpt also cites strong PAH demand and pipeline investments as supporting growth.

Why it matters — The results and Yutrepia sales provide LQDA watchers with an update on the company’s quarterly performance and growth drivers.

LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook

Zacks Investment Research · 11 Nov 2026positive

Liquidia’s Q3 earnings call highlighted surging YUTREPIA sales, record October shipments, and expanding PAH adoption, alongside post-settlement market changes and referral disruptions.

Why it matters — The update gives LQDA watchers information on product uptake and the market conditions described by the company after the settlement.

Liquidia Q3 Earnings Call Highlights

MarketBeat · 10 Nov 2026positive

Liquidia reported that third-quarter YUTREPIA sales increased 31% sequentially. On its earnings call, the company sought to reassure investors that its pulmonary arterial hypertension business can keep growing after its patent settlement with United Therapeutics.

Why it matters — The sales increase and the company’s comments on continued growth provide context on LQDA’s business following the patent settlement.

Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript

Seeking Alpha · 10 Nov 2026neutral

The item is a Seeking Alpha transcript of Liquidia Corporation’s Q3 2026 earnings call; the excerpt provides no further details about the call.

Why it matters — LQDA watchers can note that a Q3 2026 earnings-call transcript is available, though the provided excerpt does not describe company updates.

FAQ

Frequently asked questions about LQDA stock

What is the LQDA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Liquidia Corp. have a median 12-month price target of $67, with estimates ranging from $40 to $87. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LQDA stock a buy right now?

Of the 8 analysts covering Liquidia Corp., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Liquidia Corp. 97 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LQDA?

As at 17 Nov 2026, Liquidia Corp. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will LQDA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +17.9% from the last close, and Ticker Nerd's factor model ranks Liquidia Corp. 97 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LQDA stock forecast for 2030?

No analyst covering Liquidia Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LQDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $87 over the next 12 months.

How has LQDA stock performed over the past year?

Liquidia Corp. returned +86.8% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Liquidia Corp. do?

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats.

What is the latest news on LQDA?

The most recent item we track (Seeking Alpha, 14 Nov 2026): "Liquidia: Yutrepia's PAH Franchise Has Room To Grow". Liquidia retained the right to market YUTREPIA for PAH under its settlement with United Therapeutics. The settlement limits the drug’s potential in PH-ILD, while YUTREPIA is already generating cash and can still be sold to PAH patients and patients already using it.

Company

About Liquidia Corp.

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats. Liquidia’s work spans product development, manufacturing, and commercialization, giving it a role across the full lifecycle of specialty respiratory medicines. Its marketed and investigational programs are aimed at patients with challenging respiratory and vascular conditions, positioning the company within the rare-disease and specialty pharmaceutical markets. Liquidia Corporation is headquartered in Morrisville, North Carolina.

CEO Dr. Roger A. Jeffs Ph.D. · 216 employees · United States · https://www.liquidia.com